描述 |
Bisacodyl是刺激性泻剂,能直接刺激结肠产生排便活动。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
在DMSO中10mM
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
CC(OC1=CC=C(C(C2=CC=C(OC(C)=O)C=C2)C3=NC=CC=C3)C=C1)=O |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
磺丁醚-beta-环糊精 | 环孢菌素 | 2,7-二氯二氢代荧光黄二醋酸 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐 | 4′,4”-双-2-咪唑啉-2-基对苯二丙烯酰苯胺二盐酸盐 | 乙莫克舍 | TD139 | Mitoquinone甲磺酸盐 | GSK2795039 | 5,5’,6,6’-四氯-1,1’,3,3’-四乙基苯并咪唑羰花青碘化物 | 胞内钙荧光探针 BAPTA-AM | AP20187 | GKT137831 | D-虫荧光素游离酸 | 野百合碱 |
密度 | 1.2 g/cm3 |
---|---|
沸点 | 492?C |
熔点 | 131 – 135?C |
分子式 | C22H19NO4 |
分子量 | 361.39100 |
精确质量 | 361.13100 |
PSA | 65.49000 |
LogP | 4.11240 |
外观性状 | 白色至灰白色结晶粉末 |
储存条件 | 2-8°C |
稳定性 | Stable. Incompatible with strong oxidizing agents. |
计算化学 |
1.疏水参数计算参考值(XlogP):3.8 2.氢键供体数量:0 3.氢键受体数量:5 4.可旋转化学键数量:7 5.互变异构体数量:无 6.拓扑分子极性表面积:65.5 7.重原子数量:27 8.表面电荷:0 9.复杂度:457 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
|
比沙可啶毒性英文版
|
符号 |
GHS07 |
---|---|
信号词 |
Warning |
危害声明 |
H315-H319-H335 |
警示性声明 |
P305 + P351 + P338 |
个人防护装备 |
dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) |
Xi:Irritant |
风险声明 (欧洲) |
R22;R36/37/38 |
安全声明 (欧洲) |
S26-S36 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | SM8750000 |
海关编码 | 2942000000 |
比沙可啶上游产品? 10 | |
---|---|
|
|
|
|
|
|
比沙可啶下游产品? 0 |
海关编码 | 2933399090 |
---|---|
中文概述 | 2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
[Bowel preparation for colonoscopy: comparative study using Boston Bowel Preparation Scale]. Acta Gastroenterol. Latinoam. 42(3) , 186-92, (2012)
Most comparative studies on different preparations for colonic cleanliness use unvalidated scales with terms as “excellent,” “good,” “fair,” and “poor” which lack standardized definitions. The Boston …
|
|
Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release. Int. J. Pharm. 409(1-2) , 9-18, (2011)
κ-Carrageenan is a novel pelletisation aid with high formulation robustness and quick disintegration leading to fast drug release unlike the matrix-like release from non-disintegrating microcrystallin…
|
|
Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. Gastroenterology 147(4) , 903-24, (2014)
|
|
LA96A |
laco |
neolax |
zetrax |
durolax |
laxine |
EINECS 210-044-4 |
MFCD00038039 |
ivilax |
Bicol |
deficol |
Laxans |